The objective of this Multidisciplinary Clinical Research Center at the Medical University of South Carolina is the advancement of knowledge with respect to African Americans who have, or who are at risk of developing, systemic lupus erythematosus, systemic sclerosis, and other debilitating rheumatic diseases. The Center is built on a solid framework of strong leadership in Rheumatology, Biostatistics and Health Disparities Research coupled with trust and a proven track record of recruitment of African American patients for clinical research. Objectives of the Center are to: 1) conduct and foster translational clinical research leading to improved diagnosis, management and ultimately a reduction or elimination of health disparities with respect to debilitating rheumatic diseases in African Americans;2) focus on identifying and understanding the underlying reasons for differences in risk profiles and disease progression for African Americans;3) provide information and education to patients and families, healthcare providers, the general public, investigators and health professionals at other academic health centers and government agencies. We propose two innovative, high impact projects supported by three cores. Project 1 will investigate a genetic variant observed in African American SSc patients likely to be responsible for their higher severity of pulmonary fibrosis. This is highly significant given the morbidity and mortality rates, especially related to lung disease, in these patients. Project 2 addresses another significant health disparity, the increasing prevalence of lupus among African American women. The Sea Island Gullah people of South Carolina and individuals living in the Gullah ancestral home of Sierra Leone provide a novel opportunity to study genetic, environmental and epigenetic differences that might identify key factors associated with the development of SLE in African Americans. These two projects and future pilot projects will be served by three cores: (1) a Methodology Core will provide rigorous methodological and biostatistical support;(2) a Patient Resource Core will assure investigators access to patients and biological samples from SSc and SLE patients enriched with African Americans;(3) an Administrative Core will coordinate the work of the Center through planning, development, coordination and overall administration. With a sustained commitment of strong institutional support and through a robust pilot project program, this MCRC will attract and nurture young investigators with research interests in minority health and rheumatic diseases.

Public Health Relevance

The ultimate goal of the Center is to facilitate the translation of research to the clinical arena and to support much needed genetic and environmental research on rheumatic diseases affecting minorities and women disproportionately. The proposed projects and cores are focused on two autoimmune connective tissue diseases, scleroderma and lupus, each of which has profound implications for the health of the public, and each of which has a disproportionate impact on the African American community.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Comprehensive Center (P60)
Project #
5P60AR062755-02
Application #
8493999
Study Section
Special Emphasis Panel (ZAR1-KM (M1))
Program Officer
Wang, Yan Z
Project Start
2012-07-01
Project End
2017-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
2
Fiscal Year
2013
Total Cost
$1,095,546
Indirect Cost
$435,757
Name
Medical University of South Carolina
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Putterman, Chaim; Wu, Alan; Reiner-Benaim, Anat et al. (2016) SLE-key(®) rule-out serologic test for excluding the diagnosis of systemic lupus erythematosus: Developing the ImmunArray iCHIP(®). J Immunol Methods 429:1-6
Deng, Yun; Zhao, Jian; Sakurai, Daisuke et al. (2016) Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production. Ann Rheum Dis 75:2007-2013
Zhao, Jian; Giles, Brendan M; Taylor, Rhonda L et al. (2016) Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA. Ann Rheum Dis 75:242-52
Toci, Ashley L; Hyer, J Madison; Silver, Richard M et al. (2016) Systemic Sclerosis and Perceptions of Quality in Primary Care. Am J Med Sci 351:447-51
Wolf, Bethany J; Spainhour, John C; Arthur, John M et al. (2016) Development of Biomarker Models to Predict Outcomes in Lupus Nephritis. Arthritis Rheumatol 68:1955-63
Liu, Ke; Kurien, Biji T; Zimmerman, Sarah L et al. (2016) X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome. Arthritis Rheumatol 68:1290-300
Atanelishvili, Ilia; Shirai, Yuichiro; Akter, Tanjina et al. (2016) M10, a caspase cleavage product of the hepatocyte growth factor receptor, interacts with Smad2 and demonstrates antifibrotic properties in vitro and in vivo. Transl Res 170:99-111
Zhou, Zejun; Ding, Miao; Huang, Lei et al. (2016) Toll-like receptor-mediated immune responses in intestinal macrophages; implications for mucosal immunity and autoimmune diseases. Clin Immunol 173:81-86
Ramos, Paula S; Silver, Richard M; Feghali-Bostwick, Carol A (2015) Genetics of systemic sclerosis: recent advances. Curr Opin Rheumatol 27:521-9
Lu, Xiaoming; Zoller, Erin E; Weirauch, Matthew T et al. (2015) Lupus Risk Variant Increases pSTAT1 Binding and Decreases ETS1 Expression. Am J Hum Genet 96:731-9

Showing the most recent 10 out of 58 publications